

*Robert Coughlin and the Massachusetts
Biotechnology Council*

cordially invite you to:

Metabolic Disease Innovators's Roundtable: An MBC Disease Foundation Day

** Where science meets business **

Tuesday, May 5, 2009

7:30 am - 2:00 pm

**Massachusetts Biotechnology Council
One Cambridge Center, 9th Floor, Cambridge MA**

Join us for a one day, high impact roundtable discussion of leading scientific, clinical and business leaders in the metabolic space convened to address metabolic disease- from innovation to commercialization - in a challenging funding environment. You will be joined by such diverse leaders as:

- ☞ Mason Freeman, Lipid Metabolism Unit, Department of Medicine Center for Computational and Integrative Biology, Massachusetts General Hospital
- ☞ Jose Florez, Department of Molecular Biology, Massachusetts General Hospital, Boston, Massachusetts
- ☞ Brock Reeve, Harvard Stem Cell Institute
- ☞ Paul Burn, formerly at Juvenile Diabetes Research Foundation
- ☞ Richard Insel, Juvenile Diabetes Research Foundation
- ☞ Paul Feldman, Glaxo Smith Kline
- ☞ Jeff Elton, Novartis Biomedical Institute for Research
- ☞ Stephen Faraci, Pfizer, Inc.
- ☞ Albert Seymour, Pfizer, Inc.
- ☞ Tom Hughes, Zafgen, Inc.

**Massachusetts Biotechnology Council
Presents
Metabolic Disease Innovators's Roundtable: An MBC Disease Foundation Day
One Cambridge Center, 9th Floor, Cambridge MA
May 5, 2009, 7:30 am - 2:00 pm**

Metabolic Disease Innovators Roundtable- Where science meets clinical meets business

The Metabolic Disease Innovators's Roundtable is a one day, high impact roundtable discussion of leading scientific, clinical and business leaders in the metabolic space convened to address metabolic disease - from innovation to commercialization - in a challenging funding environment.

The Massachusetts life sciences supercluster represents one of the global centers of excellence for healthcare innovation and entrepreneurship; yet, market forces may ignore commercialization of necessary innovation to meet unmet medical needs. Although new players and models for funding are emerging, new thinking is required (especially in the current economic climate)-involving all stakeholders across the healthcare value chain, from patient advocates to entrepreneurs to big pharma.

The focus of this meeting is to identify critical early stage innovations in the field of metabolism that need to be assured funding to secure the flow of innovations longer-term.

MBC is bringing together disease foundations, academia, venture, biopharma and pharma companies to address how key stakeholders across the healthcare value chain can create an integrated view towards new venture creation, product development, commercialization and ultimately delivery of healthcare in the metabolic space.

Agenda Overview

Welcome

7:30am-8:00am Breakfast and networking

8:15am-8:30am Welcoming remarks (Bob Coughlin) and agenda overview

8:30am-10:00am

I. Metabolic Disease Diagnosis And Therapy- The Next Decade

10:00am-noon

II. Patient Welfare And Advocacy- A Drug Development View

Noon-1:30 pm

III. RESILIENT BIOTECHNOLOGY COMPANIES- NEW BUSINESS MODELS FOR BIOTECHNOLOGY

Noon-1:30 pm
Working Lunch

1:30pm-2:00pm
IV. Recommendations

PROGRAM DESCRIPTION

I. Metabolic Disease Diagnosis And Therapy- The Next Decade

Moderated by Tom Hughes, CEO of Zafgen

Metabolic diseases affect nearly a quarter of the US adult population. Within this subset, diabetes prevalence is expected to be approximately 18 million by 2010; worldwide sales of diabetes medications are expected to hit \$33Bn by 2010. This rise in diabetes prevalence is fueled by a dramatic increase in obesity: there now are more adults in the US who are classified as 'obese' than 'overweight'. With such sobering statistics, this discussion focuses on strategic views towards improving metabolic control and how next generation diagnostic and therapeutic strategies must be deployed.

Despite significant promise that was expected from the discovery of high-impact and common disease genes for obesity and diabetes, whole genome association studies have failed to uncover clear drug targets for these diseases. This leaves us needing alternative models for diagnosis and intervention, and requiring breakthrough ideas and treatment paradigms. What new pathways need to be explored? Are the current approaches to beta cell function likely to yield breakthrough therapies? Is mitochondrial control a pathway of the future? In what ways do the biology of aging and/or clock function intersect with metabolic control? How can obesity be managed as a fundamental driver of the epidemic? How will genomic medicine (personalized medicine) fit into next generation healthcare?

II. Patient Advocacy And Disease Foundations- A Drug Development View

Moderated by Skip Irving, Partner and Managing Director, Health Advances

Disease foundations possess significant expertise important to value based inflection points along the biotechnology value chain. Because patient advocacy groups are intimately connected with their patient populations, a patient-centric view towards drug development offers unique perspectives towards developing medicines better suited to patients.

This discussion segment will examine how and where patient advocacy groups can assist the drug development process. The group will address issues, such as:

- can working with foundations provide better tailored drugs, enlist the cooperation of patients towards successful launch, and create better phase IV monitoring practices?
- can foundations leverage tissue banking to assist therapeutic and diagnostic development?
- What role will novel imaging techniques and diagnostic testing play in patient care?
- are there better models for improving efficiencies around recruiting for multi-center trials?
- How can epigenomics and GWAS be utilized identifying specific patient types for diagnostics and treatment?

III. Resilient Biotechnology Companies- New Business Models For Biotechnology

Moderated by Jeff Elton, Global COO, Novartis Biomedical Institute for Research

The current financing structures for seed and early stage biotechnology companies are increasingly inadequate to sustain such companies through to scientific proof of concept (and beyond). Accordingly, many promising therapies will never make it to market; disease foundations, however, have stepped up to fund specific drug pipelines.

This discussion will focus on new funding paradigms- involving stakeholders and shareholders- that enable new companies to weather attritional forces. At issue:

- could disease foundations fund early stage biotechnology companies, provide bridge funding at the very early stages, provide scientific guidance at the earliest stages of the biotechnology life cycle?
- how can academia affirmatively contribute to funding new companies arising from academia?
- is there opportunity for foundations to invest in disclosed technology to get to scientific proof of concept?
- how should we fund pre-competitive collaborative research?
- are industry and/or foundation supported research consortia the most effective way to produce pre-competitive discoveries?

IV. Recommendations

The result of the day's discussion will be an MBC abstract that captures the views and recommendations of the participants. The identity of participants will remain confidential and only the organization names will be published as part of the abstract. The group will be tasked with developing a series of action items that, if implemented, would create tangible improvements in patient-physician-developer communications, create opportunities around

innovation, streamline drug development, and generate an integrated view between drug developers, patients, regulators and clinicians towards new medicines.